-
experience in AI-generated GPRC5B-targeting nanobodies and the functional characterisation of nanobodies in relation to GPRC5B signalling. Planned secondments will provide hands-on experience in the generation
-
investigated as drug targets. The aim of the project is to understand how the orphan receptor is activated and signals, develop high-throughput screening assays and identify drug-like modulators. You will use
-
system and metabolism interact in metabolic syndrome and related conditions. By combining advanced technologies with simple blood tests, the project aims to identify early biological warning signals before
-
machine-learning approaches. Established markers such as neurofilament light chain (NfL) and GFAP will provide a biological reference point for identifying disease-specific biomarkers. A central part of the
-
biological reference point for identifying disease-specific biomarkers. A central part of the project is the use of iPSC-derived models, including oligodendrocytes, astrocytes, neurons and myelinating
-
candidate in October/November 2026. Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS doctoral candidate positions that better match their
-
deadline is 5 October 2026. We aim to select a final candidate in October/November 2026. Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS
-
hiring assessment may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct). Internal candidates will be given priority over
-
hiring test may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct). Internal candidates will be given priority over